RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022